CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™

CeQur, a Switzerland-based company focused on simplifying mealtime insulin delivery for diabetes patients, has successfully closed a $100 million Series E financing round. This funding, announced on June 9, 2026, is aimed at accelerating the company's growth and expanding the reach of its innovative product, CeQur Simplicity. The investment underscores sustained investor confidence in CeQur's commercial trajectory and its potential to meet the increasing demand for more accessible insulin delivery solutions.

CeQur Simplicity is a wearable insulin patch designed to provide a convenient, injection-free method for mealtime dosing. The device has been clinically validated to improve glycemic control among users, with significant improvements in A1C levels and time-in-range metrics compared to traditional multiple daily injections. The recent funding will enable CeQur to expand its field sales team and strengthen relationships with healthcare providers, enhancing the adoption of CeQur Simplicity across primary care and endocrinology practices nationwide.

The Series E financing reflects CeQur's strong commercial momentum and the growing demand for simpler insulin delivery methods. The company plans to utilize the capital to broaden its product offerings, including extended wear capabilities and various dosage options, thereby catering to a wider patient demographic. This strategic move aligns with the increasing trend in the diabetes management sector towards more user-friendly and effective treatment options, as patients and healthcare providers seek alternatives to conventional insulin delivery methods.

Investor confidence in CeQur is bolstered by compelling clinical evidence supporting the efficacy of CeQur Simplicity, which has shown that nearly 90% of patients adhere better to their insulin regimens when using the patch. Furthermore, with over 85% of claims covered as a pharmacy benefit and an average copay of less than $45 per month, the financial accessibility of the product is likely to enhance its market penetration.

The successful closure of this financing round not only positions CeQur for significant growth but also highlights broader trends within the diabetes management sector. As the demand for innovative, patient-centric solutions continues to rise, companies like CeQur will play a crucial role in transforming diabetes care. The infusion of capital and the strategic expansion of CeQur's commercial operations are expected to drive further advancements in insulin delivery technology, ultimately benefiting patients seeking simpler and more effective management of their diabetes.